Gyros AB and Kratos Analytical collaboration is a success

10-Mar-2003

Gyros AB today announced the success of their collaboration with Kratos Analytical, begun in May 2002. Users of the Axima-QITTM and Axima-CFRTM plus line of mass spectrometry workstations will soon be able to benefit from using GyrolabTM MALDI for sample preparation prior to analysis.

Gyros offers a miniaturized and fully integrated process for sample preparation prior to MALDI mass spectrometry, using a microlaboratory in the form of a compact disk (CD), Gyrolab MALDI SP1, that can be run under automated conditions. Protein digests are concentrated, purified and crystallized directly onto target areas on the CD under the control of Gyrolab Workstation. The CD is transferred to an AXIMA MALDI mass spectrometer for sample analysis and protein identification.

Results demonstrate that sample preparation using Gyrolab MALDI SP1 produces samples that can be analyzed at higher sensitivity levels than those achieved using conventional preparation techniques.

Mr. Ichimura, Managing Director of Kratos Analytical, explained, “MALDI mass spectrometry is a well established technology for protein identification and well prepared samples will always give the best analytical results. High sensitivity not only improves identification rates, but facilitates the identification of low abundant proteins that are key interest in proteomics research.

Improved sensitivity, high reproducibility and the ability to process up to 96 samples in parallel offer a significant step towards greater productivity and a higher success rate for protein identification. Fully automated analysis of the samples on the Gyrolab MALDI SP1 CD is now possible using the IntelliMarqueTM software of the Axima instruments which is designed for identification of proteins from peptide mass fingerprints and data-dependent seamless PSD.”

Maris Hartmanis, President and CEO at Gyros AB stated, “This collaboration has run very smoothly. We confirmed at an early stage that our microlaboratory format was suitable for use in Kratos mass spectrometers. The two companies then worked closely together and, within a few months, produced accessories and software necessary for smooth operation. Gyrolab Workstation and Gyrolab MALDI SP1 are now fully compatible with Kratos instrumentation. Products are now available for Axima-CFR. Final verification work on Axima-QIT is in progress, and we are confident of a successful outcome.”

About Kratos

Kratos Analytical Limited is a wholly owned subsidiary of the Shimadzu Corporation of Kyoto, Japan, selling and distributing its MALDI mass spectrometry products through the global Shimadzu Biotech business organisation. Its strengths lie in the quality of design, in the excellence of products and in the commitment to partnerships with customers.

Kratos Analytical employs innovative strategies in the development of MALDI MS products, including the unique patented curved field reflectron of the Axima-CFR for controlled seamless post source decay fragmentation of peptides, and the novel Axima-QIT hybrid MALDI quadrupole ion trap time-of-flight mass spectrometer, for detailed structural determination of biomolecules.


Enquiries:
For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: katie.odgaard@zymecommunications.com / lorna.cuddon@zymecommunications.com
www.zymecommunications.com


Notes to editors:
About Gyros (www.gyros.com)

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.